<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02917681</url>
  </required_header>
  <id_info>
    <org_study_id>401922/2014-6</org_study_id>
    <nct_id>NCT02917681</nct_id>
  </id_info>
  <brief_title>Study of Two Intrathecal Doses of Autologous Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pontifícia Universidade Católica do Paraná</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to evaluate primarily safety of two injections of autologous mesenchymal stem
      cells in Amyotrophic Lateral Sclerosis patients. Secondary outcomes of efficacy will also be
      evaluated
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is an open-label, unmasked, uncontrolled phase I and II trial to evaluate safety
      and efficacy of two injections of autologous mesenchymal stem cells (MSC) in Amyotrophic
      Lateral Sclerosis (ALS) patients. Patients will be recruited trough a web-based registration
      system, open for all ALS Brazilian patients. The patients will be enrolled after in-person
      screening at the University of Sao Paulo Medical School Clinics Hospital and inclusion
      criteria fulfilled. There will be 9 national calls for registration, two months apart each.
      The enrolled patients will be followed for 3 months before bone marrow aspiration (BMA).
      Patients will receive 2 intrathecal MSC injections, 1 and 2 months after BMA. The patients
      will be followed for 6 months after the interventions.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>10 months</time_frame>
    <description>Clinical and laboratory monitoring of possible reactions to intrathecal MSC delivery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R)</measure>
    <time_frame>10 months</time_frame>
    <description>Specific scale for assessing ALS disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Handheld dynamometry</measure>
    <time_frame>10 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Electrical Impedance Myography</measure>
    <time_frame>10 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Forced Vital Capacity (FVC)</measure>
    <time_frame>10 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Isometric Strength</measure>
    <time_frame>10 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in morphometric parameters of MRI of encephalon and spinal cord</measure>
    <time_frame>10 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>AMYOTROPHIC LATERAL SCLEROSIS</condition>
  <arm_group>
    <arm_group_label>MSC injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be followed for 3 months before bone marrow aspiration (BMA). Patients will receive 2 intrathecal MSC injections, 1 and 2 months after BMA. The patients will be followed for 6 months after the interventions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Two intrathecal MSC injections</intervention_name>
    <arm_group_label>MSC injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age between 18 and 70

          2. Possible, probable or definite ALS following El Escorial Revised Criteria (Brooks,
             2000)

          3. ALSFRS-r ≥30 at enrollment

          4. Forced Vital Capacity ≥65% of the height and weight standard

          5. No-pregnancy agreement

          6. Regional accessibility to the study site

          7. Capability to give away agreed consensus

          8. Patients will be followed at Academic Institutions at their hometown

        Exclusion Criteria:

          1. Previous cellular therapy

          2. Incapacity to lay still during bone marrow aspirate or intrathecal MSC injections

          3. Personal history of auto-Immune, myeloproliferative or myelodysplastic diseases,
             leukemia, lymphoma, whole-body irradiation, hip fracture, severe scoliosis or
             incapacity to undergo any of the study's proposed procedures

          4. Any other disease that may interfere with the study

          5. Any other neurological diseases

          6. Aspartate or alanine aminotransferases elevated &gt;3x normality upper limit

          7. Serum creatinine &gt;2x normality upper limit

          8. Hepatitis B and C, HIV, HTLV I and II and syphilis

          9. Immunosuppressant drug use within 6 weeks from the study's screening

         10. Pregnancy or breast-feeding

         11. Acquired or inherited Immunodeficiency

         12. Participation in other clinical trials

         13. Non-invasive ventilation, tracheostomy or diaphragm pacing

         14. Substance abuse within one year and other unstable mental health diseases according to
             researcher's judgement

         15. Gastrostomy or any alternative feeding means

         16. Inappropriate in-vitro MSC expansion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerson Chadi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Full Professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabrício Castro Borba, MD</last_name>
    <phone>551130617460</phone>
    <email>contato@projetoelabrasil.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jéssica Ruivo Maximino, PhD</last_name>
    <phone>551130617460</phone>
    <email>contato@projetoelabrasil.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Sao Paulo School of Medicine Clinics Hospital</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05403000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2016</study_first_submitted>
  <study_first_submitted_qc>September 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2016</study_first_posted>
  <last_update_submitted>September 27, 2016</last_update_submitted>
  <last_update_submitted_qc>September 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo General Hospital</investigator_affiliation>
    <investigator_full_name>Gerson Chadi</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>ALS</keyword>
  <keyword>mesenchymal stem cells</keyword>
  <keyword>intrathecal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

